Evogene

Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. It operates through the following segments: Agriculture, Industrial Applications, and Human Health. The Agriculture segment develops seed traits, agrochemical products, and agro biological products to improve plant performance. The Industrial Applications focuses on the development and commercialization of improved castor bean seeds for industrial uses. The Human Health segment involves discovery and development of human microbiome-based therapeutics. The company was founded by Amir Barzilay and Hagai Karchi on October 10, 1999 and is headquartered in Rehovot, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Evogene reports revenue growth and strategic collaborations driving future prospects

Evogene's Q1 2024 performance showed revenue growth, decreased losses, and strategic milestones achieved by key subsidiaries.
The company's strengths lie in innovative collaborations, a unique CPB platform, and successful revenue-driving partnerships.
Challenges include financial management, operational execution, and logistical considerations for seed supply.
Opportunities for growth stem from promising future achievements, strategic partnerships, and market differentiation through innovation.

Evogene reports revenue surge and promising developments in key segments

Evogene demonstrated strong revenue growth in the first half of 2024 and made progress in reducing losses, reflecting improving financial performance.
Casterra's expanding market reach and revenue growth opportunities, coupled with Biomica's promising trial results, position Evogene well for future growth.
While facing challenges in achieving profitability and managing cash flow, Evogene's focus on operational efficiency and market expansion presents avenues for sustainable growth.

Evogene reports Q3 revenue decline but anticipates growth opportunities

Evogene's Q3 2024 performance reflected a decline in revenues but improved cost management, with a focus on enhancing cash reserves.
The company's strengths lie in upcoming revenue growth, strategic collaborations, and plans to fortify its financial position.
Challenges include market uncertainties, operational losses, and addressing investor concerns for sustained growth and profitability.
Opportunities exist for Evogene to capitalize on its achievements, explore new avenues, and drive value creation for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

REHOVOT, Israel, Jan. 18, 2022 /PRNewswire/ -- Canonic Ltd., focused on the development of medical grade cannabis products and a wholly-owned subsidiary of Evogene Ltd.

Canonic Announces Positive Results in Pre-Clinical Studies in its Precise Product Program for Medical Cannabis

REHOVOT, Israel, Jan. 11, 2022 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd.

Biomica Announces Clearance for First-in-Human Phase I Study of BMC-128 in Combination with Bristol Myers Squibb's Anti-PD-1 Opdivo®

REHOVOT, Israel, Dec. 14, 2021 /PRNewswire/ -- Lavie Bio Ltd., a leading ag-biologicals company focusing on improving food quality and agricultural productivity and sustainability through the introduction of microbiome-based products, and a subsidiary of Evogene Ltd.

Lavie Bio Reports Advancement in its Bio-Fungicide Program for Fruit Rots

REHOVOT, Israel, Nov. 30, 2021 /PRNewswire/ -- Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), reported today positive results from pre-clinical studies in its IBD program.

Biomica Reports Positive Results from Pre-Clinical Studies in its Inflammatory Bowel Disease (IBD) Program

Evogene (EVGN) CEO, Ofer Haviv on Q3 2021 Results - Earnings Call Transcript

Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), the parent company of medical cannabis-focused Canonic, reported its financial results Wednesday for the first nine months and third quarter of 2021.

Evogene Reports Slight YoY Boost In Q3 Revenue, Looks To Turn Subsidiaries Into Public Companies

REHOVOT, Israel, Nov. 17, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today its financial results for the first nine months and the third quarter of 2021, ended September 30, 2021.

Evogene Reports Third Quarter 2021 Financial Results

REHOVOT, Israel, Nov. 10, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product development across several market segments, announced today that it has been informed by the Israeli Innovation Authority (IIA) of the IIA's decision to fund a second 18-month period of the CRISPR-IL consortium established last year.

Evogene Announces Participation in the Second Research Period of the CRISPR-IL Consortium

REHOVOT, Israel, Nov. 3, 2021 /PRNewswire/ -- Lavie Bio Ltd., a subsidiary of Evogene Ltd.

Lavie Bio Announces Commercial Launch of its First Microbiome-Based Product for Yield Improvement - result™

REHOVOT and HAIFA, Israel, Oct. 27, 2021 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd.

Biomica & Rambam Health Care Campus Sign Agreement for Clinical Trial of Biomica's Microbiome-Based Immuno-Oncology Drug

REHOVOT, Israel, Oct. 27, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announces today that it will release its financial results for the third quarter of 2021 on Wednesday, November 17th, 2021.

Evogene Financial Results and Earnings Announcement Schedule for the Third Quarter of 2021

Canopy Growth

Flora Growth Corp

Greenlane Holdings

HEXO Corp

High Tide

Tilray Brands

Welcome back to our weekly series,  Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up in 2021.

See Why a Slew of Pot Stocks Made the News This Week

Evogene Ltd.'s (NASDAQ:EVGN) (TASE: EVGN) wholly-owned subsidiary focused on developing medical cannabis products, Canonic Ltd.

Evogene's Canonic Launches First Two Medical Cannabis Products In Israel Ahead Of Schedule

REHOVOT, Israel, Oct. 19, 2021 /PRNewswire/ -- Canonic Ltd., focused on the development of medical cannabis products and a wholly-owned subsidiary of Evogene Ltd.

Canonic Announces Full Commercial Launch of its First Medical Cannabis Products in Israel

REHOVOT, Israel and BERTHOLD, N.D., Sept. 29, 2021 /PRNewswire/ -- Lavie Bio Ltd.

Lavie Bio and United Agronomy Announce Signing of Distribution Agreement for Lavie Bio's Inoculant Product

REHOVOT, Israel, Sept. 14, 2021 /PRNewswire/ -- Evogene Ltd.

Evogene to Present at Cantor Virtual Global Healthcare Conference, September 2021

Canonic introduces their new proprietary cannabis strains and begins limited distribution in Israel. The company will make a full commercial release of the new products in 2022.

Evogene's Canonic Begins Selling High THC Cannabis In Israeli Medical Market

Evogene (EVGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Evogene (EVGN) a New Buy Stock

REHOVOT, Israel, Sept. 1, 2021 /PRNewswire/ -- Evogene Ltd.

Evogene to Present at H.C. Wainwright 23rd Annual Global Investment Conference - 2021

REHOVOT, Israel, Aug. 31, 2021 /PRNewswire/ -- Canonic Ltd, a company focused on the development of medical cannabis products and a wholly owned subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today the pre-launch of its first-generation medical cannabis inflorescence products.

Canonic Announces Pre-Launch of its First Generation Medical Cannabis Products in Israel

Evogene Ltd. (EVGN) CEO Ofer Haviv on Q2 2021 Results - Earnings Call Transcript

Biotechnology company Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) posted its financial results Wednesday for the first half and second quarter of 2021 along with a proclamation from the company's president and CEO Ofer Haviv in which he said that this fiscal year is “turning out to be a key strategic year for unlocking value at Evogene and its subsidiaries.

Evogene Reports $135.000 In Q2 2021 Revenue, Misses Estimates, EPS Beat Projections By $0.02

REHOVOT, Israel, Aug. 11, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across several market segments, announced today its financial results for the first half and the second quarter of 2021, ended June 30, 2021.

Evogene Reports Second Quarter 2021 Financial Results

REHOVOT, Israel, July 29, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announced today that Ofer Haviv, Evogene's President and CEO, will present at the Jefferies Virtual Industrials Conference, 2021 taking place on August 3-4,2021.

Evogene to Present at Jefferies Virtual Industrials Conference, 2021

REHOVOT, Israel, July 28, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announces today that it will release its financial results for the second quarter of 2021 on Wednesday, August 11th, 2021.

News for Evogene Stock (EVGN)